OrbiMed raises $3bn to back global life science players - Pharmaceutical Technology

The duo of funds will support companies across the biopharma, healthcare technology, diagnostics and medical device disciplines. The duo of funds will support companies across the life sciences landscape – including those in the biopharma, healthcare technology and medtech disciplines. OrbiMed will allocate capital to companies across the biopharma, medtech, diagnostics and technology-enabled healthcare segments. Credit: Visual Generation / Shutterstock.com. Global healthcare investment giant OrbiMed has raised $3bn for two new private equity funds to support the growth of companies across the European, US and Asian life sciences sectors. This raise has seen OrbiMed establish two new funds. The first,…

Source: Pharmaceutical Technology